Mon, Feb 12, 2018 - Page 5 News List

OxyContin maker to stop pushing opioids to doctors

NOT ONLY IN US:A critic said opioids were designed for cancer patients with severe pain, but promoted as a treatment for chronic pain because it is more profitable

AP, NEW YORK

The maker of the powerful painkiller OxyContin said it will stop marketing opioid drugs to doctors, bowing to a key demand of lawsuits that blame the company for helping trigger the current drug abuse epidemic.

OxyContin has long been the world’s top-selling opioid painkiller, bringing in billions in sales for privately held Purdue, which also sells a newer and longer-lasting opioid drug called Hysingla.

The company announced its surprise reversal on Saturday.

Purdue’s statement said it eliminated more than half its sales staff this week and will no longer send sales representatives to doctors’ offices to discuss opioid drugs. Its remaining sales staff of about 200 will focus on other medications.

The OxyContin pill, a time-release version of oxycodone, was hailed as a breakthrough treatment for chronic pain when it was approved in late 1995. It worked over 12 hours to maintain a steady level of oxycodone in patients suffering from a wide range of pain ailments.

However, some users quickly discovered they could get a heroin-like high by crushing the pills and snorting or injecting the entire dose at once.

In 2010 Purdue reformulated OxyContin to make it harder to crush and stopped selling the original form of the drug.

Purdue eventually acknowledged that its promotions exaggerated the drug’s safety and minimized the risks of addiction.

After US federal investigations, the company and three executives pleaded guilty in 2007 and agreed to pay more than US$600 million for misleading the public about the risks of OxyContin.

However, the drug continued to rack up blockbuster sales.

Andrew Kolodny, director of opioid policy research at Brandeis University and an advocate for stronger regulation of opioid drug companies, said Purdue’s decision is helpful, but it will not make a major difference unless other opioid drug companies do the same.

“It is difficult to promote more cautious prescribing to the medical community because opioid manufacturers promote opioid use,” he said.

Allergan, which makes three opioid pain medications, said it has not actively marketed those drugs in years, and Janssen Pharmaceuticals, a unit of Johnson & Johnson, said it stopped marketing the medications in 2015. Both said opioid drugs make up a very small portion of their total revenue.

Drugmaker Insys said it was not able to comment immediately, while Teva Pharmaceutical Industries did not immediately respond to a request for comment.

Kolodny said that opioids are useful for cancer patients who are suffering from severe pain, and for people who only need a pain medication for a few days.

However, he said the companies have promoted them as a treatment for chronic pain, where they are more harmful and less helpful, because it is more profitable.

“They are still doing this abroad,” Kolodny added. “They are following the same playbook that they used in the United States.”

Purdue Pharma only does business in the US, but it is associated with two other firms, Mundipharma and Napp, that operate in other countries. It said those companies have separate leadership and operate according to local regulations.

Purdue and other opioid drugmakers and pharmaceutical distributors continue defending themselves against hundreds of local and state lawsuits seeking to hold the industry accountable for the drug overdose epidemic.

This story has been viewed 1297 times.

Comments will be moderated. Remarks containing abusive and obscene language, personal attacks of any kind or promotion will be removed and the user banned.

TOP top